{
    "title": "GlaxoSmithKline and Swiss rival Novartis sign multi-part deal that will create consumer health powerhouse",
    "url": "https://www.dailymail.co.uk/money/markets/article-2609703/GSK-bribery-investigations-spread-11-countries.html",
    "date": "2014-04-21",
    "keywords": [
        "novartis",
        "glaxosmithkline",
        "consumer",
        "health",
        "gsk",
        "year",
        "cent",
        "deal",
        "powerhouse",
        "business",
        "glaxo",
        "company",
        "rival",
        "multipart",
        "part",
        "sector",
        "range",
        "savlon",
        "china",
        "news",
        "come",
        "pfizer",
        "group",
        "world",
        "transaction",
        "glaxos",
        "surrey",
        "healthcare",
        "jordan",
        "emergency",
        "abbas",
        "hussain",
        "sign",
        "peter",
        "campbell",
        "mail",
        "money",
        "reporter",
        "gmt",
        "april",
        "email",
        "view",
        "today",
        "string",
        "oncology",
        "portfolio",
        "cough",
        "brand",
        "tixylix",
        "higher",
        "announcement",
        "morning",
        "trading",
        "astrazeneca",
        "takeover",
        "drug",
        "firm",
        "bid",
        "thing",
        "development",
        "price",
        "division",
        "flu",
        "half",
        "return",
        "capital",
        "headquarters",
        "frimley",
        "berkshire",
        "weybridge",
        "executive",
        "sir",
        "scale",
        "combine",
        "quality",
        "core",
        "value",
        "bribery",
        "multiplythe",
        "giant",
        "dozen",
        "corruption",
        "number",
        "staff",
        "lebanon",
        "iraq",
        "back",
        "compliance",
        "host",
        "arab",
        "kuwait",
        "syria",
        "allegationssavvas",
        "analyst",
        "panmure",
        "gordon",
        "problem",
        "pharma",
        "evidence",
        "companys"
    ],
    "category": [
        "money",
        "markets"
    ]
}